About Us

Mr. LIU Gexin

Chairman of the Board and non-Executive Director

Mr. LIU Gexin was appointed as a Director and the chairman of the Board in November 2016 and March 2022, respectively. He was redesignated as our non-Executive Director on February 15, 2023. He is mainly responsible for overseeing the management and strategic development of the Group.

Mr. Liu is the founder of Kelun Pharmaceutical and has served as the chairman of Kelun Pharmaceutical since its establishment. From November 2020 to October 2022, he served as a director of Kelun Research Institute. In addition, Mr. Liu currently has also held positions in a number of subsidiaries of Kelun Group, including (i) the chairman of Sichuan Kelun Industry Group Co., Ltd.; (ii) the chairman of Chengdu Qingshan Likang Pharmaceutical Co., Ltd.; (iii) the chairman of Yili Chuanning Biotechnology Co., Ltd., a company listed on the Shenzhen Stock Exchange (stock code: 301301); and (iv) a director of Chengdu Huaxi Clinical Research Co., Ltd..

Mr. Liu obtained his Master's degree in cardiovascular pharmacology from Chongqing Medical College (currently known as Chongqing Medical University) in China in June 1984. Mr. Liu also obtained his another Master's degree in political economics from Southwest Normal University (currently known as Southwest University) in China in July 2003. Mr. Liu has received a series of awards and recognition, including: (i) the National Model Worker by The State Council, PRC in May 2005 and (ii) the Second Prize of National Science and Technology Progress Award by The State Council, PRC in December 2014.

Dr. GE Junyou

General Manager, Executive Director

Dr. GE Junyou was appointed as a Director in February 2022. He was redesignated as our Executive Director on February 15, 2023. Dr. Ge was appointed as the Chief Operation Officer of the Company in February 2021 and the general manager of the Company in March 2022. He is mainly responsible for overall corporate and business strategies of our Group and making key business and operational decisions of our Group. Dr. Ge has also served as a director and the Chief Executive Officer of KLUS PHARMA in US since December 2021, an Executive director of Sichuan Konas since November 2021, a director of Biotargeted Drug Engineering Research Center since March 2023 and a director of Kelun-Biotech Hong Kong Co., Limited since October 2023.

Dr. Ge has been engaged in the R&D of innovative drugs, manufacturing and quality control, and corporate management in the pharmaceutical industry at home and abroad for about 30 years. The companies he has worked for include Shanghai Yan’an Pharmaceutical Factory, Boehringer Ingelheim, Zhejiang Hisun Pharmaceutical Co., Ltd. (600267.SH) and Ratiopharm GmbH. Dr. Ge joined Kelun Pharmaceutical in June 2007 and served as a deputy general manager from July 2009 to February 2021, where he was mainly responsible for leading the quality management of Kelun Group. As a top cGMP expert in China, he participated in the revision, drafting, and review of the new Chinese GMP regulations, related guidelines and guiding principles, and co-authored five Professional Publications on GMP.

Dr. Ge obtained his bachelor's degree in pharmacy from Shanghai Medical School (currently known as Shanghai Medical College Fudan University) in China in July 1994. He obtained his Master's degree in pharmaceutical engineering from East China University of Science and Technology in November 2008. He also obtained his doctoral degree in biology and medicine from Fudan University in January 2017.

Dr. Ge is currently a standing committee member of the Sichuan Association for Science and Technology, a visiting professor at the Institute of Executive Development of NMPA, an expert reviewer for the Ministry of Science and Technology’s science and technology plan projects, a member of the Peer Review Expert Panel for the Hong Kong Innovation and Technology Commission, a member of the Drug Quality Management Committee of the Chinese Pharmaceutical Association, a member of the Anti-Cancer Drug Committee of the Chinese Pharmaceutical Association, Vice President of the China Quality Association for Pharmaceuticals, and a director of the Hong Kong Association of Overseas-Returned Scholars, etc..

Mr. LIU Sichuan

Non-Executive Director

Mr. LIU Sichuan was appointed as a Director in November 2016. He was redesignated as our non-Executive Director on February 15, 2023. He is mainly responsible for overseeing the management and strategic development of the Group.

Mr. Liu joined Kelun Pharmaceutical and served as the assistant of chairman in 2007. He has been serving as a director of Kelun Pharmaceutical since May 2009 and general manager of Kelun Pharmaceutical since September 2015. Currently he has also held positions in a number of subsidiaries of Kelun Group, including: (i) a director of Chengdu Qingshan Likang Pharmaceutical Co., Ltd. since June 2012; (ii) a manager and Executive director of Chengdu Kelun Chuaicai Enterprise Management Co., Ltd since May 2020; (iii) a director of Yili Chuanning Biotechnology Co., Ltd., a company listed on the Shenzhen Stock Exchange (stock code: 301301), since June 2020; (iv) a director of Sichuan Kelun Industry Group Co., Ltd. since September 2021; and (v) a manager and Executive director of Chengdu Kelun Jingchuan Technology Co., Ltd. since November 2021.

Mr. Liu obtained his Master's degree in international business from the University of Leeds in the United Kingdom in August 2007. Mr. Liu has received a series of awards and recognition, including “Title of Outstanding Entrepreneur in Hunan Province” issued by Hunan Provincial Committee of the CPC and the People's Government of Sichuan Province on January 2018, and “National Advanced Individual in Fighting the COVID-19” issued by CPC Central Committee, The State Council, PRC and the Military Commission of the CPC Central Committee in September 2020.

Mr. LAI Degui

Non-Executive Director

Mr. LAI Degui was appointed as a Director in June 2024. He is mainly responsible for overseeing the management and strategic development of the Group.

Mr. Lai has served as (i) a deputy general manager and financial director of Kelun Pharmaceutical since October 2014; (ii) a supervisor of Chengdu Kelun Chuanzhi Enterprise Management Co., Ltd. (成都科伦川智企业管理有限公司) since May 2020; (iii) an Executive director of Zhejiang Keyun IOT Technology Co., Ltd. (浙江科运物联科技有限公司) since December 2020; (iv) an Executive director and general manager of Shanxi Keyun IOT Technology Co., Ltd. (山西科运物联科技有限公司) since May 2021; and (v) an Executive director and general manager of (四川科志物联科技有限公司) since October 2021.

Mr. Lai received a diploma of accounting from Southwestern University of Finance and Economics (西南财经大学) through on-the-job learning in January 2013, and received a Master’s degree in business management from Tsinghua University (清华大学) in June 2023.

Mr. FENG Hao

Non-Executive Director

Mr. FENG Hao was appointed as a Director in February 2021. He was redesignated as our non-Executive Director on February 15, 2023. He is mainly responsible for overseeing the management and strategic development of the Group.

Mr. Feng has been serving as a deputy general manager and secretary of board of directors of Kelun Pharmaceutical since April 2014. He also served as a non-Executive director of SSY Group Limited, a company listed on the Stock Exchange (stock code: 02005), from November 2017 to November 2023.

From July 2002 to August 2003, Mr. Feng served as a tutor at the School of Economics at Huazhong University of Science and Technology. From December 2004 to January 2005, Mr. Feng served as an analyst at the Actuarial Division of Taiping Life Insurance Company Limited. From December 2005 to December 2006, he served as an actuarial advisory consultant at Watson Wyatt Consultancy (Shanghai) Ltd. From January 2007 to August 2007, he served as a senior manager at the investment banking division of Ping An Securities Limited. From September 2007 to January 2014, he served as a business director at the investment banking division of Sinolink Securities Co. Ltd..

Mr. Feng obtained his Master’s degree in financial mathematics from Heriot-Watt University in the United Kingdom in November 2005. Mr. Feng has received a series of awards and recognition including the 2022 and 2023 5A Rating for Duty Performance of Board Secretary of Listed Companies by China Association for Public Companies on December 12, 2022 and December 6, 2023, respectively.

Mr. ZENG Xuebo

Non-Executive Director

Mr. ZENG Xuebo was appointed as a Director in July 2022. He was redesignated as our non-Executive Director on February 15, 2023. He is mainly responsible for overseeing the management and strategic development of the Group.

Formerly he served as a manager and was then promoted as a director of Shenzhen Zhongyi Yingtai Venture Capital Co., Ltd.. From June 2015 to July 2016, he served as a deputy director of Shenzhen Investment Holdings Donghai Investment Co., Ltd.. From August 2016 to October 2020, he served as a director and was then promoted as a vice president of Aiqi Venture Capital Management (Shenzhen) Co., Ltd.. He has served as a vice president and a managing director of Hexie Zhuorui (Zhuhai) Investment Management Co., Ltd. since November 2020 and March 2024, respectively. From January 2022 to September 2023, he served as a director of Hang Zhou Sciwind Biosciences Co., Ltd..

Currently he also holds positions in various companies, including (i) a director of Shandong Bestcomm Pharmaceutical Company Limited; (ii) a director of Shanghai Model Organisms Center, Inc., a company listed on the Shanghai Stock Exchange (stock code: 688265), since September 2022; (iii) a director of Chiral Quest (Suzhou) Co., Ltd., since December 2022; (iv) a director of Jiangxi Longlife Bio-pharmaceutical Co., Ltd., since February 2023; (v) a director of Suzhou Pengxu Pharmatech Co., Ltd., since February 2023; (vi) an independent director of CASI Pharmaceuticals, Inc., a company listed on NASDAQ (stock code: CASI), since March 2023; (vii) a director of Zhejiang Ablaze Medicine Co. Ltd., since March 2023;  (viii) a director of ZenCore (Cayman) Limited, since November 2023;and(ix)a director of Chengdu Pukangweixin Biotechnology Co., Ltd. since May 2024.

Mr. Zeng obtained his bachelor's degree in pharmacy from Qinghai Minzu University in China in July 2009.

Mr. LI Dongfang

Non-Executive Director

Mr. LI Dongfang was appointed as a Director in February 2022. He was redesignated as our non-Executive Director on February 15, 2023. He is mainly responsible for overseeing the management and strategic development of the Group.

From August 2011 to March 2015, Mr. Li served as an analyst of Goldman Sachs (Asia) L.L.C. He has been serving as an Executive director of SDIC Investment Management Co., Ltd. since August 2015, where he is responsible for equity investment. He has been a director of Hainan Simcere Zaiming Pharmaceutical Co., Ltd. since July 2024.

Mr. Li obtained his bachelor's degree and Master's degree in electronic commerce and finance from University of International Business and Economics in China in July 2009 and July 2011, respectively. He has been a Chartered Financial Analyst since June 2015.

Dr. ZHENG Qiang

Independent Non-Executive Director

Dr. ZHENG Qiang was appointed as an independent non-Executive Director on February 15, 2023 with effect from July 2023. He is mainly responsible for supervising and providing independent advice on the operation and management of our Group.

Dr. Zheng joined the Peking University in 2005, and served as a professor and doctoral supervisor in industrial engineering and management in Peking University until his retirement on January 27, 2024.

Dr. Zheng obtained his bachelor's degree in physics from Peking University in China in July 1983. Dr. Zheng obtained his Master's degree in physics from Graduate School of Chinese Academy of Sciences (currently known as University of Chinese Academy of Sciences in China in August 1986. He also obtained his doctoral degree in physics from Temple University in the United States in June 1989.

Dr. TU Wenwei

Independent Non-Executive Director

Dr. TU Wenwei was appointed as an independent non-Executive Director on February 15, 2023 with effect from July 2023. He is mainly responsible for supervising and providing independent advice on the operation and management of our Group.

Dr. Tu successively served as a lecturer and attending doctor at the department of paediatrics of Children’s Hospital, Chongqing Medical University and a postdoctoral researcher fellow in the department of pediatrics at the Stanford University School of Medicine in the United States before 2006. Dr. Tu has served as a professor in the department of paediatrics & adolescent medicine, Li Ka Shing Faculty of Medicine at The University of Hong Kong (the “HKU”) since June 2015. Dr. Tu also held various positions, such as the assistant dean of the Li Ka Shing Faculty of Medicine since October 2011 and an associate professor since June 2009 at the department of paediatrics & adolescent medicine since joining HKU in 2006.

Dr. Tu obtained his bachelor's and Master's degrees in medicine sciences from Chongqing Medical University in the PRC in July 1989 and December 1992, respectively. He obtained his doctoral degree in philosophy from HKU in December 1999. Dr. Tu has received a series of awards including several Prize of Science and Technology Progress. He was also recognized as a Changjiang scholar chair professor in pediatrics by Ministry of Education of PRC in April 2016.

Dr. JIN Jinping

Independent Non-Executive Director

Dr. JIN Jinping was appointed as an independent non-Executive Director on February 15, 2023 with effect from July 2023. She is mainly responsible for supervising and providing independent advice on the operation and management of our Group.

Dr. Jin serves as an associate professor in the Law School, Peking University. She has been serving as an independent director of China Automotive Engineering Research Institute Co., Ltd., a company listed on the Shanghai Stock Exchange (stock code: 601965), since January 2020, and an independent non-Executive Director of Horizon Construction Development Limited, a company listed on the Stock Exchange (stock code: 9930), since May 2021. Dr. Jin served as an independent director of Beijing WKW Automotive Parts Co., Ltd., a company listed on the main board of the Shenzhen Stock Exchange (stock code: 002662), from January 2014 to May 2020；an independent director of Beijing Oriental Jicheng Co., Ltd., a company listed on the Shenzhen Stock Exchange (stock code: 002819), since July 2018 to July 2024. 

Dr. Jin obtained a bachelor's degree in economic law from Peking University in the PRC in July 1995, a Master's degree in civil and commercial law from Peking University in July 2001, and a doctorate degree in civil and commercial law from Peking University in June 2004. Dr. Jin obtained a lawyer qualification granted by the Ministry of Justice of the PRC in June 1997 and higher education teacher qualification granted by the Beijing Municipal Education Commission in December 2008. Dr. Jin has served as a director of the China Red Cross Foundation since September 2016.

Dr. LI Yuedong

Independent Non-Executive Director

Dr. LI Yuedong was appointed as an independent non-Executive Director on February 15, 2023 with effect from the Listing Date. She is mainly responsible for supervising and providing independent advice on the operation and management of our Group.

Dr. Li joined the Southwestern University of Finance and Economics in 2004 and she has been serving as a doctoral supervisor in Auditing in Southwestern University of Finance and Economics since January 2022. She has been serving as (i) an independent director of Chengdu Sino Microelectronics Technology Co., Ltd., a company listed on the Shanghai Stock Exchange in January 2024 (stock code: 688709), since September 2021; (ii) an independent director of Ya’an Baitu High Tech Materials Co., Ltd. since September 2022; (iii) an independent director of Chengdu Zhimingda Electronics Co., Ltd., a company listed on the Shanghai Stock Exchange (stock code: 688636), since November 2022; (iv) an independent director of Chengdu Shengbang Seals Co., Ltd., a company listed on the Shenzhen Stock Exchange (stock code: 301233), since November 2022; (v) an external supervisor of Sichuan Beichuan Rural Commercial Bank Co., Ltd. since December 2023; and (vi) an independent non-Executive director of Honghua Group Limited, a company listed on the Hong Kong Stock Exchange (stock code: 196), since June 2024. In addition, Dr. Li also served as (i) an independent director of Kelun Group from June 2015 to June 2021; (ii) an independent director of Chengdu Hi-Tech Development Co., Ltd., a company listed on the Shenzhen Stock Exchange (stock code: 000628) from June 2015 to June 2022; (iii) an independent director of Sichuan Fengsheng Paper Technology Co., Ltd. from December 2019 to December 2022; (iv) an independent director of Sichuan Neautus Traditional Chinese Medicine Co., Ltd. from January 2020 to February 2023; and(v)an independent director of Chengdu Leejun Industrial Co., Ltd. from July 2021 to May 2024, a company listed on the Shenzhen Stock Exchange (stock code: 002651).

Dr. Li obtained her bachelor’s degree in economics from Chongqing Business College (currently known as Chongqing Technology and Business University) in China in July 2000. Dr. Li obtained her Master’s degree in accountancy from Georgia College & State University in the United States in May 2004. She also obtained her doctoral degree in business administration from Southwestern University of Finance and Economics in China in January 2011, completed the joint post-doctoral program between the National Audit Office of China and Peking University in 2015 and served as a research fellow of the Institute of Chartered Accountants in England and Wales (ICAEW) in 2021. Dr. Li was appointed as an external doctoral supervisor for the DBA at Lyon Business School, France, in July 2022 and was certified as a public accountant by the Board of Accountancy of Guam, the United States, in August 2015. She also participated numerous times in United Nations audit projects of the National Audit Office of China and completed audit training course in the United Nations in June 2020. Dr. Li has received a series of awards and recognition. She was recognized as an internationalized high-end accounting talent by Ministry of Finance of the PRC in December 2021.